{"disease":{"id":"red-eye","name":"Red eye","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"crospovidone","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Povidone","generic_name":"CROSPOVIDONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Antiseptic [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"tetryzoline","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocuzolin","generic_name":"tetryzoline","company_name":"Fougera Pharms","drug_phase":"marketed","molecular_target":"Adrenergic receptor alpha","drug_class":"tetryzoline","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"macrogol","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miralax","generic_name":"Macrogol","company_name":"Braintree","drug_phase":"marketed","molecular_target":"","drug_class":"Osmotic Laxative [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"antazoline","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenazoline","generic_name":"ANTAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"antazoline","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"dextran","indication_name":"redness of the eye due to minor eye irritations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"GoodSense Eye Drops Advanced Relief Moisturizer","generic_name":"DEXTRAN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"","drug_class":"Plasma Volume Expander [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"zinc-sulfate","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinc Sulfate","generic_name":"ZINC SULFATE","company_name":"Am Regent","drug_phase":"marketed","molecular_target":"","drug_class":"zinc sulfate","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"polyvinyl-alcohol","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vinyl Alcohol Polymer","generic_name":"POLYVINYL ALCOHOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Polyvinyl alcohol works by forming a protective barrier on the surface of the eye to help repair and maintain the tear film."},{"drug_id":"naphazoline","indication_name":"Red eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Naphcon Forte","generic_name":"NAPHAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Non-Standardized Chemical Allergen [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05247333","title":"Implementation of a Minor Ailment Service in Community Pharmacy Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":20987,"lead_sponsor_name":"Universidad de Granada","has_results":false},{"nct_id":"NCT03814863","title":"China Red Eye Study","phase":"","overall_status":"COMPLETED","enrollment_count":4382,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT00001732","title":"Screening for Studies on Inherited Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT00011817","title":"Evaluation and Treatment of Patients With Inherited Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT06538662","title":"An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":283,"lead_sponsor_name":"Alcon Research","has_results":false},{"nct_id":"NCT05184621","title":"The Effectiveness and Safety of Low-intensity Single-wavelength Red Light in Controlling High Myopia in Children and Adolescents：A Randomized, Controlled, Multicenter Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT03305484","title":"Soft Contacts Observation of Risk and Education (SCORE)","phase":"","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"Southern California College of Optometry at Marshall B. Ketchum University","has_results":false},{"nct_id":"NCT06596733","title":"Vit-A-Vision® Clinical Investigation","phase":"NA","overall_status":"RECRUITING","enrollment_count":77,"lead_sponsor_name":"OmniVision GmbH","has_results":false},{"nct_id":"NCT06034912","title":"Fundus Effects of Repeated Low-Level Red-Light Therapy in Chinese Myopic Minors: A Randomized Controlled Clinical Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06893913","title":"Effect of Addition of Pyramidal Exercise to Intermittent Fasting on Dryness of Eye in Pre-diabetic Psoriasis Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT03872479","title":"Single Ascending Dose Study in Participants With LCA10","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Editas Medicine, Inc.","has_results":false},{"nct_id":"NCT03994406","title":"Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Glia, LLC","has_results":false},{"nct_id":"NCT03396042","title":"Natural History Study of CEP290-Related Retinal Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Editas Medicine, Inc.","has_results":false},{"nct_id":"NCT03780257","title":"Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"ProQR Therapeutics","has_results":false},{"nct_id":"NCT06159569","title":"Performance and Tolerability of the Medical Device LACRIACT","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Laboratórios Baldacci S.A","has_results":false},{"nct_id":"NCT07341763","title":"Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Waterloo","has_results":false},{"nct_id":"NCT03913130","title":"Extension Study to Study PQ-110-001 (NCT03140969)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT05158296","title":"Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT05176717","title":"Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Laboratoires Thea","has_results":true}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}